Kangmei Pharmaceutical Co Ltd

Kangmei Pharmaceutical released its 2026 interim report. Total operating revenue was 2.29 billion yuan, and net profit attributable to the parent company was 36.0348 million yuan, an increase of 19.1334 million yuan compared with the same period last year, marking five consecutive years of growth and a year-on-year rise of 113.21%. Net cash inflow from operating activities was 36.0528 million yuan, an increase of 118 million yuan over the same period last year, achieving growth for two consecutive years. The company's asset-liability ratio was 43.66%, down 1.41 percentage points from the previous quarter and down 3.37 percentage points from the same period last year. Gross margin was 21.30%, up 2.46 percentage points year on year, rising for two consecutive years. Return on equity was 0.49%, up 0.26 percentage points from a year earlier. Diluted earnings per share rose 200.00% year on year. Total asset turnover was 0.17 times, and inventory turnover was 0.79 times. The number of shareholders was 285,900, and the top ten shareholders held 4.646 billion shares, accounting for 33.59% of total share capital.

Kangmei Pharmaceutical released its 2026 interim report, showing first-half net profit attributable to the parent of 36.03 million yuan, up 113.2% year on year. Operating revenue was 2.29 billion yuan, down 11.1% year on year. Net profit attributable to the parent after deducting non-recurring items swung from a loss of 3.62 million yuan in the same period last year to a loss of 59.59 million yuan, with the loss widening further. Second-quarter net profit attributable to the parent was 52.6 million yuan, up 526.5% year on year. The company said that during the reporting period it actively advanced centralized procurement business, successfully winning bids for 41 product varieties, and that e-commerce channel sales performed well.

Kangmei Pharmaceutical has won the first-instance trial in a recovery rights dispute. The court ordered Ma Xingtian and Xu Dongjin to pay approximately 1.396 billion yuan to the company. Qiu Xiwei bears supplementary liability within the scope of about 142 million yuan, and Guangdong Zhengzhong Zhujiang Certified Public Accountants bears supplementary liability within the scope of about 141 million yuan. Previously, the company was ordered by the Guangzhou Intermediate People's Court to compensate 52,037 investors for investment losses of approximately 2.459 billion yuan due to financial fraud. After completing all compensation in the bankruptcy reorganization process, it filed a recovery lawsuit against the responsible parties. This first-instance judgment supported part of the company's recovery claims.